Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina

<div>The upper panel (a) shows a diffuse positive MGMT control (glioblastoma). The lower panel (b) corresponds to a negative MGMT immunostaining of macrocorticotropinoma in patient GM.</div>

International Journal of Endocrinology

fig1

Figure 1

Figure 1: Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina 